{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:24:29Z","timestamp":1791051869320,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jbspin.2018.09.017","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T01:34:34Z","timestamp":1538357674000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation"],"prefix":"10.1016","volume":"86","author":[{"given":"Karine","family":"Briot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Paccou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Bonneterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Bouvard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille B.","family":"Confavreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Hannoun-L\u00e9vi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose-Marie","family":"Javier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lespessailles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Mayeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Mongiat Artus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Vieillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Debiais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2018.09.017_bib0005","unstructured":"Les cancers en France\/Edition 2016. Institut National du Cancer. www.e-cancer.fr"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0015","unstructured":"Guide \u2013 Affection de longue dur\u00e9e. Cancer de la prostate. HAS\/INCa Janvier 2012. https:\/www.has-sante.fr\/"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.292.7.821","article-title":"6-month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial","volume":"292","author":"D\u2019Amico","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0030","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10\u2013year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0035","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0040","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0045","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0050","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0065","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0075","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S1166-7087(16)30705-9","article-title":"CCAFU French national guidelines 2016\u20132018 on prostate cancer","volume":"27","author":"Rozet","year":"2016","journal-title":"Prog Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0080","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s00198-013-2530-3","article-title":"Cancer-associated bone disease","volume":"24","author":"Rizzoli","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0085","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN Task Force report: bone health in cancer care","volume":"11","author":"Gralow","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0090","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0100","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00198-013-2343-4","article-title":"Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D","volume":"24","author":"Alibhai","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0105","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0110","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.urology.2004.07.019","article-title":"Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression","volume":"64","author":"Higano","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0115","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","article-title":"Bone mineral density changes in prostate cancer patients during the first two years of androgen suppression","volume":"175","author":"Morote","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0125","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.pcan.4500599","article-title":"Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss","volume":"5","author":"Preston","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0135","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.bone.2008.05.003","article-title":"Incidence and risk factors for low trauma fractures in men with prostate cancer","volume":"43","author":"Ahlborg","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0140","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1464-410X.2009.08458.x","article-title":"Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study","volume":"104","author":"Spry","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0145","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2011.38.3745","article-title":"Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer","volume":"30","author":"Yu","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.urology.2004.03.036","article-title":"Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy","volume":"64","author":"Conde","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0155","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0165","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1464-410X.2007.07163.x","article-title":"Fracture risk in Danish men with prostate cancer: a nationwide register study","volume":"100","author":"Abrahamsen","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0170","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","article-title":"Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications","volume":"111","author":"Shao","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jbmr.1771","article-title":"Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy","volume":"28","author":"Greenspan","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","article-title":"High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study","volume":"39","author":"Angeli","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0190","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","article-title":"Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men","volume":"184","author":"Alibhai","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0195","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.juro.2011.03.111","article-title":"Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer","volume":"186","author":"Saylor","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0200","first-page":"4908","article-title":"Fracture risk in androgen deprivation therapy: a Canadian population based analysis","volume":"16","author":"Lau","year":"2009","journal-title":"Can J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(96)01440-7","article-title":"Fall-related factors and risk of hip fracture: the EPIDOS prospective study","volume":"348","author":"Dargent-Molina","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0210","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.urology.2010.11.024","article-title":"Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study","volume":"77","author":"Bylow","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0215","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jocd.2015.06.013","article-title":"Executive summary of the 2015 ISCD position development conference on advanced measures from DXA and QCT: fracture prediction beyond BMD","volume":"18","author":"Shepherd","year":"2015","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0220","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/JCD:5:3S:S19","article-title":"What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians?","volume":"5","author":"Binkley","year":"2002","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0230","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1385\/JCD:5:1:087","article-title":"Implications in the use of T scores for the diagnosis of osteoporosis in men","volume":"5","author":"Faulkner","year":"2002","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jocd.2006.05.004","article-title":"Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD official positions","volume":"9","author":"Leslie","year":"2006","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0240","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jbspin.2008.07.014","article-title":"Male osteoporosis: diagnosis and fracture risk evaluation","volume":"76","author":"Briot","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0245","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0250","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.lpm.2011.04.001","article-title":"La vitamine D chez l\u2019adulte\u2009: recommandations du GRIO","volume":"40","author":"Benhamou","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0255","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00432-014-1706-3","article-title":"Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis","volume":"140","author":"Xu","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0260","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.canep.2009.10.014","article-title":"Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk","volume":"33","author":"Yin","year":"2009","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0265","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ijc.25439","article-title":"Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma","volume":"128","author":"Gandini","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0270","first-page":"319","article-title":"Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis","volume":"22","author":"Gilbert","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0275","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0280","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1359\/JBMR.040813","article-title":"Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer","volume":"19","author":"Morabito","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0285","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.eururo.2005.01.012","article-title":"Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate","volume":"47","author":"Magno","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0290","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0295","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0300","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0305","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","article-title":"Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy","volume":"182","author":"Bhoopalam","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0310","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0315","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1464-410X.2009.08622.x","article-title":"Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis","volume":"104","author":"Planas","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0320","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","volume":"63","author":"Klotz","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0325","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/j.1464-410X.2010.09329.x","article-title":"Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer","volume":"106","author":"Taxel","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0330","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","article-title":"Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy","volume":"85","author":"Choo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0335","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","article-title":"Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.jbspin.2018.09.017_bib0340","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18303476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18303476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:24:48Z","timestamp":1761150288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X18303476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1297319X18303476"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.09.017","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}